Molecule
Rimabotulinumtoxinb is an acetylcholine release inhibitor indicated for treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults, among other approved uses. MedsAcross supplies Rimabotulinumtoxinb for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MYOBLOC is an acetylcholine release inhibitor indicated for: Treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults. Treatment of chronic sialorrhea in adults
Source: US FDA prescribing information
MYOBLOC blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerved terminals. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin), a presynaptic target protein essential for the release of acetylcholine. In both muscles and glands, impulse transmission is re-established by the formation of new nerve endings.
Source: US FDA prescribing information
Cervical Dystonia: for patients with demonstrated tolerance of botulinum toxin injection, recommended total dosage is 2,500 Units to 5,000 Units divided among effected muscles. Chronic Sialorrhea: recommended dosage is 1,500 Units to 3,500 Units, 500 Units to 1,500 Units per parotid gland and 250 Units per submandibular gland, no more frequent than every 12 weeks
Source: US FDA prescribing information
MYOBLOC is contraindicated in patients with: A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation Infection at the proposed injection site(s) MYOBLOC is contraindicated in patients with: Known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation. Infection at the proposed injection site(s)
Source: US FDA prescribing information
Boxed warning (distant spread of toxin effect): Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. Spread of toxin effects, swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or swallowing difficulties occur. MYOBLOC potency units cannot be compared to or converted into units of other botulinum toxins. Patients with neuromuscular disorders should be monitored closely for swallowing/breathing difficulty
Source: US FDA prescribing information
The following clinically significant adverse reactions to MYOBLOC are discussed in greater detail in other sections of the labeling: Spread of Toxin Effect Lack of Interchangeability Between Botulinum Toxin Products Hypersensitivity Reactions Dysphagia and Breathing Difficulties Human Albumin and Transmission of Viral Diseases The most common adverse reactions (>5% of MYOBLOC-treated patients at any dose and >5% more common than placebo) include: Cervical Dystonia: dry mouth, dysphagia, injection site pain, and headache. Chronic Sialorrhea: dry mouth and dysphagia
Source: US FDA prescribing information
Co-administration with aminoglycosides or other agents interfering with neuromuscular transmission may potentiate effects of MYOBLOC. Co-administration or overlapping of botulinum toxin serotypes (within 4 months) may potentiate neuromuscular paralysis
Source: US FDA prescribing information
Store under refrigeration at 2°C to 8°C (36°F- 46°F) in the original carton to protect from light. DO NOT FREEZE. DO NOT SHAKE.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Rimabotulinumtoxinb, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Myobloc 10000 units/2 mL injectionIntramuscular Cold chain | Solstice Neurosciences | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Rimabotulinumtoxinb in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Rimabotulinumtoxinb and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Rimabotulinumtoxinb, including Myobloc.
At least one listed presentation of Rimabotulinumtoxinb must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.